Tokyo, Aug. 15 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062582) titled 'Study of the Effectiveness and Safety of Drug Therapy Including Immune Checkpoint Inhibitors for Unresectable Advanced Invasive Mucinous Adenocarcinoma of the Lung' on Aug. 14.
Study Type:
Observational
Primary Sponsor:
Institute - Specified Nonprofit Corporation North East Japan Study Group
Condition:
Condition - Unresectable advanced or recurrent invasive mucinous adenocarcinoma of the lung
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To evaluate the efficacy and safety of immune checkpoint inhibitor-based therapy in patients with unresectable advanced i...